Please assess the completion status of the following clinical trial:

Trial Title: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Genetically confirmed DMD~2. Reduced upper arm strength as measured by the Performance of Upper Limb~3. Reduced ability to walk/run (if ambulatory)~4. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments~5. Current and up-to-date immunizations~Exclusion Criteria:~1. Left ventricular ejection fraction \< 35%~2. BMI \> 45~3. Ambulant if ≥ 18 years of age~4. Exon 44 skip-amenable mutation(s) in the DMD gene~5. Deletion mutation(s) encompassing exons 3-7 of the DMD gene~6. Percent-predicted forced vital capacity (FVC) \< 35%~7. Chronic respiratory disease not related to DMD (for example, asthma, bronchitis, and tuberculosis)~8. History of diabetes requiring treatment with metformin or insulin within 3 months prior to randomization~9. Treatment with an FDA-approved exon skipping therapy for the treatment of DMD if on a stable dose for less than 24 months prior to randomization~10. Treatment with human growth hormone (HGH) within 3 months prior to randomization, unless on a stable dose for at least 24 months prior to randomization~11. Treatment with idebenone within 3 months prior to randomization~12. Treatment with a cell therapy product within 12 months prior to randomization~13. Treatment with an investigational product within 6 months prior to randomization

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAP-1002 (Type: EXPERIMENTAL): Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).